Literature DB >> 8433868

Calcium kinetics in the hyperprostaglandin E syndrome.

L Shoemaker1, T R Welch, W Bergstrom, S A Abrams, A L Yergey, N Vieira.   

Abstract

Metabolic investigations, including the use of stable isotopes of calcium, were used to study calcium kinetics in three children with the hyperprostaglandin E syndrome. The studies were performed both during indomethacin treatment and in the absence of therapy. Off therapy, each child had hypercalciuria (mean urinary calcium excretion 0.478 mM/kg/d), hyperprostaglandinuria, and elevated serum calcitriol concentration. All had diminished bone density and were euparathyroid. Indomethacin treatment was associated with a marked reduction in serum calcitriol concentration, as well as decreased prostaglandin E excretion. Mean urinary calcium excretion fell to 0.135 mM/kg/d. The stable isotope studies defined two components to the hypercalciuria of this disease: an indomethacin-sensitive dietary contribution and a relatively indomethacin-resistant bone resorptive element. Bone densitometry confirmed the presence of the resorptive element by demonstrating skeletal demineralization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8433868     DOI: 10.1203/00006450-199301000-00019

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  12 in total

Review 1.  Hypercalcemia in children and adolescents.

Authors:  Steven A Lietman; Emily L Germain-Lee; Michael A Levine
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

2.  Bone mineral density and bone turnover in patients with Bartter syndrome.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Mireia Aguirre
Journal:  Pediatr Nephrol       Date:  2005-06-08       Impact factor: 3.714

3.  Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome.

Authors:  R Vargas-Poussou; D Feldmann; M Vollmer; M Konrad; L Kelly; L P van den Heuvel; L Tebourbi; M Brandis; L Karolyi; S C Hebert; H H Lemmink; G Deschênes; F Hildebrandt; H W Seyberth; L M Guay-Woodford; N V Knoers; C Antignac
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

4.  Effect of nonsteroidal anti-inflammatory drugs in children with Bartter syndrome.

Authors:  Gaël Gasongo; Larry A Greenbaum; Olivier Niel; Theresa Kwon; Marie-Alice Macher; Anne Maisin; Véronique Baudouin; Claire Dossier; Georges Deschênes; Julien Hogan
Journal:  Pediatr Nephrol       Date:  2018-11-13       Impact factor: 3.714

5.  Gitelman's syndrome is genetically distinct from other forms of Bartter's syndrome.

Authors:  L Károlyi; A Ziegler; M Pollak; M Fischbach; K H Grzeschik; M C Koch; H W Seyberth
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

6.  Severe hyperprostaglandin E syndrome with hyperthyroidism--studies of pathogenetic mechanisms.

Authors:  V Fellman; H Pihko; A Majander; H W Seyberth
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

7.  How can you differentiate neonatal Bartter's syndrome from hyperprostaglandin (-uria) E2 syndrome?

Authors:  H W Seyberth
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

8.  Pre-pubertal growth in the hyperprostaglandin E syndrome.

Authors:  C Seidel; S Reinalter; H W Seyberth; K Schärer
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

9.  A novel compound heterozygous ROMK mutation presenting as late onset Bartter syndrome associated with nephrocalcinosis and elevated 1,25(OH)(2) vitamin D levels.

Authors:  Amita Sharma; Micheal A Linshaw
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

10.  Precise determination of the absorptive component of urinary calcium excretion using stable isotopes.

Authors:  T R Welch; S A Abrams; L Shoemaker; A L Yergey; N Vieira; J E Stuff
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.